What were Wockhardt Ltd's latest quarterly results?
Wockhardt Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +205.0%
- Revenue Growth YoY: +23.2%
- Operating Margin: 20.0%
Wockhardt Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. PE: 178.0. ROE: -1.2%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on publicly available financial data. This is educational research, not investment advice.
Wockhardt Ltd's latest quarterly results (Dec 2025) show
Wockhardt Ltd's current PE ratio is 178.0x.
Wockhardt Ltd's price-to-book ratio is 4.2x.
Wockhardt Ltd's fundamental strength based on key financial ratios
Wockhardt Ltd has a debt-to-equity ratio of N/A.
Wockhardt Ltd's return ratios over recent years
Wockhardt Ltd's operating cash flow is negative (FY2025).
Wockhardt Ltd currently does not pay a significant dividend (yield 0.00%).
Wockhardt Ltd's shareholding pattern (Dec 2025)
Wockhardt Ltd's promoter holding has remained stable recently.
Wockhardt Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Based on quantitative research signals, here is why Wockhardt Ltd may be worth studying
Wockhardt Ltd investment thesis summary:
Wockhardt Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.